sirolimus

However, sirolimus stents fared better than paclitaxel stents in terms of MI, target vessel revascularization, and late thrombosis.

Stent thrombosis after 1 year was more common with both sirolimus-eluting stents and paclitaxel-eluting stents than with bare-metal stents.

Drug discontinuation due to an adverse event was also more frequent in the sirolimus cohort compared to those patients continued on CNI.

Therapeutic drug monitoring should not be the sole basis for adjusting sirolimus therapy.

Kushwaha and colleagues tested the use of sirolimus as an alternative anti-proliferative immunosuppressant drug.

A novel, simple and cost effective assay for monitoring blood levels of rapamycin (sirolimus) and rapamycin analogues was developed.

Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving kidney transplants.

At this time, FDA has not made any changes to the professional label for sirolimus.

Sirolimus monotherapy may be safe, but experience is limited and side effects such as hyperlipidemia must be monitored.

In all 4 patients, sirolimus-induced pneumonitis resolved following cessation of therapy but took weeks to months for complete recovery.

Beyond 2 years, the increase in plaque volume, but not plaque index, was significantly lower with sirolimus than calcineurin inhibitors.

Objective To observe the effect of application of Sirolimus on adventitia in preventing stenosis of vein graft.

Sirolimus is a kind of macrolide antibiotics as well as immunosuppressant.

The FDA is determining whether a labeling change for sirolimus is needed.

The effect of sirolimus, a new immunosuppressant, on vaccine responses has been little studied.

Immunosuppression included de noo sirolimus, low-dose calcineurin inhibitor for 6 to 12 months, with short-course (3 months) or no steroids.

The synergic effects of sirolimus and immature dendritic cells in prolonging survival time of skin allograft in mice

Determination of the plasma sirolimus concentrations in patients after renal transplantation by HPLC method

Study of sirolimus-eluting stent in treatment of elderly pretty long coronary artery lesions

Sirolimus inhibits the differentiation, proliferation and migration of endothelial progenitor cells in vitro

Analysis of acute and subacute stent thrombosis after successful implantation of sirolimus-eluting stent in complex coronary lesions

Comparison of the application of sirolimus eluting stents and paclitaxel eluting stents in coronary lesions

Nine cases of conversion from calcineurin inhibitor to sirolimus in the treatment of urological neoplasm in kidney allograft recipients

Clinical observation on sirolimus- eluting stent implantation in left main coronary artery bifurcation lesions

One-year clinical outcomes of domestic sirolimus-eluting stent in treating unselected patients with coronary artery disease

The clinical efficacy of sirolimus-eluting stents versus paclitaxel-eluting stents in complex and diffuse coronary lesions

Clinical and angiographic follow-up observation of sirolimus-eluting stents in the treatment of complex coronary lesions

Short-term clinical observation of low-dose sirolimus in living relative kidney transplantation from elderly donor

Evaluation of clinical outcomes of sirolimus-eluting stents treated to coronary bifurcation lesions

The impact of expansion of sirolimus eluting stent on intimal hyperplasia: an intravascular ultrasound study

Sirolimus-eluting stents with modified T-stenting technique for reverse crushing on bifurcation lesions

Determination of peroxide value in sirolimus oral solution by potentiometric-iodometry

The Efficacy of Sirolimus-eluting Stents and Bear Metal Stents in Treatment of Atherosclerotic Coronary Lesion

Compare homemade sirolimus-eluting stent to paclitaxel-eluting stent with clinical effect

Safety and efficacy of sirolimus eluting stent in patients with small renal artery stenotic lesions

Comparison of sirolimus eluting stenting versus bare metal stenting in type 2 diabetic patients with very small coronary artery lesions

Effects of sirolimus on recurrence of cancer after liver transplantation

Effect of Sirolimus on preventing transplant arteriosclerosis in rats

Advances in the Study of Preventing Coronary Restenosis with Sirolimus Eluting Stent

Application of Sirolimus-Eluting Stents in Patients with Coronary Artery Disease and Type 2 Diabetes

Sirolimus, a new agent for prevention of renal graft rejection

The stability of sirolimus in whole blood

Of 186 liver transplant patients receiving sirolimus, 4 (2. 2%) developed pneumonitis that was attributed to the drug;